Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2021; 12(2):562-570. doi:10.7150/jca.45899 This issue Cite

Research Paper

18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions

Anne M. Hendriks1, Adrienne H. Brouwers2, Panagiotis Giannopoulos1, Joop D. Lefrandt3, Wim Timens4, Harry J.M. Groen5, Geertruida H. de Bock6, Mathilde Jalving1✉

1. University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Department of Medical Oncology.
2. University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Department of Nuclear Medicine and Molecular Imaging.
3. University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Department of Internal Medicine.
4. University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Department of Pathology.
5. University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Department of Pulmonary Diseases.
6. University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Department of Epidemiology.

✉ Corresponding author: M. Jalving, MD, PhD, Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, Postbus 30.001, 9700 RB Groningen, The Netherlands. Phone: 00 31 50 3612821, Fax: 00 31 50 3614862, E-mail: m.jalving More

Citation:
Hendriks AM, Brouwers AH, Giannopoulos P, Lefrandt JD, Timens W, Groen HJM, de Bock GH, Jalving M. 18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. J Cancer 2021; 12(2):562-570. doi:10.7150/jca.45899. https://www.jcancer.org/v12p0562.htm
Other styles

File import instruction

Abstract

Background: Reprogrammed glucose metabolism is a hallmark of cancer making it an attractive therapeutic target, especially in cancers with high glucose uptake such as non-small cell lung cancer (NSCLC). Tools to select patients with high glucose uptake in the majority of tumor lesions are essential in the development of anti-cancer drugs targeting glucose metabolism. Type 2 diabetes mellitus (T2DM) patients may have tumors highly dependent on glucose uptake. Surprisingly, this has not been systematically studied. Therefore, we aimed to determine which patient and tumor characteristics, including concurrent T2DM, are related to high glucose uptake in the majority of tumor lesions in NSCLC patients as measured by 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) scans.

Methods: Routine primary diagnostic 18F-FDG PET/CT scans of consecutive NSCLC patients were included. Mean standardized uptake value (SUVmean) of 18F-FDG was determined for all evaluable tumor lesions and corrected for serum glucose levels according to the European Association of Nuclear Medicine Research Ltd guidelines. Patient characteristics potentially determining degree of tumor lesion glucose uptake in the majority of tumor lesions per patient were investigated.

Results: The cohort consisted of 102 patients, 28 with T2DM and 74 without T2DM. The median SUVmean per patient ranged from 0.8 to 35.2 (median 4.2). T2DM patients had higher median glucose uptake in individual tumor lesions and per patient compared to non-diabetic NSCLC patients (SUVmean 4.3 vs 2.8, P < 0.001 and SUVmean 5.4 vs 3.7, P = 0.009, respectively). However, in multivariable analysis, high tumor lesion glucose uptake was only independently determined by number of tumor lesions ≥1 mL per patient (odds ratio 0.8, 95% confidence interval 0.7-0.9).

Conclusions: 18F-FDG PET/CT scans can identify sub-groups of NSCLC patients with high glucose uptake in the majority of their tumor lesions. T2DM patients had higher tumor lesion glucose uptake than non-diabetic patients. However, this was not independent of other factors such as the histological subtype and number of tumor lesions per patient.

Keywords: 18F-FDG PET/CT, non-small cell lung cancer, glycolysis, type 2 diabetes mellitus

Citation styles

APA
Hendriks, A.M., Brouwers, A.H., Giannopoulos, P., Lefrandt, J.D., Timens, W., Groen, H.J.M., de Bock, G.H., Jalving, M. (2021). 18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. Journal of Cancer, 12(2), 562-570. https://doi.org/10.7150/jca.45899.

ACS
Hendriks, A.M.; Brouwers, A.H.; Giannopoulos, P.; Lefrandt, J.D.; Timens, W.; Groen, H.J.M.; de Bock, G.H.; Jalving, M. 18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. J. Cancer 2021, 12 (2), 562-570. DOI: 10.7150/jca.45899.

NLM
Hendriks AM, Brouwers AH, Giannopoulos P, Lefrandt JD, Timens W, Groen HJM, de Bock GH, Jalving M. 18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. J Cancer 2021; 12(2):562-570. doi:10.7150/jca.45899. https://www.jcancer.org/v12p0562.htm

CSE
Hendriks AM, Brouwers AH, Giannopoulos P, Lefrandt JD, Timens W, Groen HJM, de Bock GH, Jalving M. 2021. 18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. J Cancer. 12(2):562-570.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use